CClinicalTrials.gg
CompletedNCT04312711Updated Jan 11, 2022

3D Time-of-Flight Magnetic Resonance Angiography in Hemodialysis Patients With Arteriovenous Fistula

An interventional study of 3D-TOF-MRA in Magnetic Resonance Angiography, Hemodialysis and Arteriovenous Fistula Stenosis, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2018, registered Mar 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Sex
All
01

Study summary

This study is aimed to assess the value of three-dimensional time-of-flight magnetic resonance angiography (3D-TOF-MRA) in hemodialysis patients with occlusive disease in arteriovenous fistula (AVF). All participants will receive 3D-TOF-MRA and ultrasound to detect the stenosis degree of AVF.

Read the detailed description

The Principle of 3D-TOF-MRA is based on the "flow effect" of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. Therefore as a non-invasive and safe method for diagnosing vascular diseases, 3D-TOF-MRA is used widely in cerebrovascular diseases. However, there are currently no studies using 3D-TOF-MRA to diagnose arteriovenous fistula (AVF) stenosis in hemodialysis patients. This project plans to use 3D-TOF-MRA to detect AVF stenosis in hemodialysis patients to provide a safe and effective diagnostic method for patients with end-stage renal failure.

02

Conditions studied

  • Magnetic Resonance Angiography
  • Hemodialysis
  • Arteriovenous Fistula Stenosis
03

In context

Arteriovenous Fistula

267 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

This study's enrollment of 68 is close to the median of 68 across 177 interventional studies indexed under Arteriovenous Fistula.

Browse Arteriovenous Fistula studies →

Lead sponsor

Shanghai Jiao Tong University Affiliated Sixth People's Hospital is the lead sponsor of 40 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • hemodialysis patients suspected of occlusive disease in arteriovenous fistula (AVF);
  • persistent edema of the limb with the fistula;
  • decreased pulse or fremitus in anastomotic astium
  • increase in venous pressure; blood flow at the access of less than 200 mL/min;

Exclusion criteria

Exclusion Criteria:

  • previous endovascular recanalization with stent or graft placement;
  • contraindications to magnetic resonance imaging (MRI) examination;
  • platelet(PLT)\<60*10\^9/L or international normalized ratio (INR)>1.5; 4. important organ function failure or other serious illness; 5. Allergic to antiplatelet drug, anticoagulant drug, anaesthetic drug and contrast material.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    intervention

    All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference

    Diagnostic Test: 3D-TOF-MRA

Interventions

  • Diagnostic test3D-TOF-MRA

    The Principle of 3D-TOF-MRA is based on the "flow effect" of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases.

    Also known as: Ultrasound, Digital Substraction Angiography

06

What researchers measure

Primary outcomes

  1. degree of stenosis

    visual grading system: 0 = completely smooth vessel wall; 1. = \<50% stenosis; 2. = 50%-75% stenosis; 3. = 75%-99% stenosis; 4. = occlusion.

    Time frame: immediately after examination finished

  2. stenosis location

    1. = arterial vessel of AVF 2. = orifice of AVF 3. = venous vessel of AVF

    Time frame: immediately after examination finished

07

Study locations

1 site
  • Shanghai 6th People's Hospital
    Shanghai, 200023, China
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 4, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Individual participant data will not be made avaliable.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04312711
Lead sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Yueqi Zhu (Clinical Professor, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) — Principal investigator
First posted
Mar 18, 2020
Start date
Dec 1, 2018
Primary completion
Oct 1, 2020
Completion
Mar 31, 2021
Last update
Jan 11, 2022

Study contacts

Yue-Qi Zhu, Dr
principal investigator · Shanghai 6th People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion